Brain Wealthy
    What's Hot

    Leigh-Anne Pinnock shares emotional post about embarking on her solo career

    February 2, 2023

    Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

    February 2, 2023

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Anxiety»Cybin selects generalized anxiety disorder as the target indication for the deuterated DMT molecule CYB004
    Anxiety

    Cybin selects generalized anxiety disorder as the target indication for the deuterated DMT molecule CYB004

    brainwealthy_vws1exBy brainwealthy_vws1exJanuary 12, 2023No Comments7 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Toronto – (business wire)–Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or company), a biotech company focused on advancing from psychedelics to therapeutics® today announced the targeted indication of its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, CYB004, for generalized anxiety disorder (“GAD”) with or without major depressive disorder (“MDD”). I announced that I chose it as a disease.

    “Based on preclinical data, CYB004 has shown promise for the treatment of anxiety disorders. Nearly half of people who suffer from depression also suffer from GAD, making the need for more effective treatment options for GAD all the more urgent,” said Doug Drysdale, CEO of Cybin. says. “The prevalence of depression and anxiety has risen significantly since the pandemic and through its current development program Cybin has developed a revolutionary new drug to alleviate the emotional distress experienced by so many people around the world. We are optimistic that we may be able to provide a cure. We continue to see the potential of CYB004 as a new chemical to offer new avenues for mental healing. ”

    Generalized anxiety disorder is characterized by excessive worry and tension that is not confined to specific environmental situations. Anxiety disorders are the most common mental health problem in the United States. In the United States, more than 40 million adults (her 19.1% of the total US population) suffer from anxiety disorders.1

    Other Facts About Anxiety and Generalized Anxiety Disorder:

    • Among psychiatric disorders, GAD and MDD are the leading causes of disability worldwide. The presence of both GAD and MDD is strongly associated with poor prognosis, increased severity of symptoms, decreased quality of life, increased MDD recurrence, and higher suicide risk than either disorder alone.2-5

    • GAD affects 6.8 million adults each year, or 3.1% of the US population.6

    • Women are twice as likely to be affected by GAD.6

    • Worldwide, 14.7 million people have GAD in any given year.7

    • Twenty-three percent of adults prescribed SSRI discontinuation within 4 weeks and 36.5% within 3 months. Another report showed that about half of the patients discontinued antidepressants within his three months. 8

    • With a prevalence of approximately 9%, there is a lifetime risk of GAD.9

    • Based on the 2022 Generalized Anxiety Disorder Treatment Market Report, the economic burden of GAD is expected to grow to US$12 billion by 2030.Ten

    Cybin is currently conducting a Phase 1 exploratory study (the “CYB004-E study”) evaluating IV N,N-dimethyltryptamine (“DMT”) to explore the future clinical potential of CYB004 for the treatment of GAD. Obtaining critical safety and dosing optimization data for development. To date, the CYB004-E trial has not shown any clinically significant safety or tolerability issues. Cybin hopes to translate key findings from the initial study cohort (such as dose optimization and dosing dynamics) to support the remaining cohorts planned for the trial. These findings are also expected to accelerate his Cybin plans to begin human administration of CYB004.

    In its natural form, DMT is rapidly metabolized in the body and is not orally bioavailable. Based on preclinical studies, CYB004 has the potential to overcome the limitations of DMT. Specifically, these data demonstrate that CYB004 has increased oral and pulmonary bioavailability, more rapid onset at lower doses, less intersubject variability, and potential side effects compared to oral and IV DMT. was shown to be superior due to the relatively low dose titration.

    Cybin received a US composition of matter patent covering CYB004 in February 2022.

    The company plans to provide an update on the CYB004 program by the end of February 2023.

    1. https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Anxiety-Disorders
    2. GBD 2019 (2020). collaborator in illness and injury. 369 global burden of illness and injury in 204 countries and territories, 1990-2019: A systematic analysis of studies on the global burden of illness in 2019. Lancet, 396(10258):1204–22.
    3. Zhou Y, Cao Z, Yang M, et al. (2017). Generalized anxiety disorder comorbidity and its association with quality of life in patients with major depressive disorder. Sci Rep., 7(1):40511. Doi: 10.1038/srep40511.
    4. McIntyre RS, Woldeyohannes HO, Soczynska JK et al. (2016). Prevalence and clinical features associated with anxiety disorder designators as defined in the Diagnostic and Statistical Manual Version 5 in Adults with Major Depressive Disorder: Results of the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis., 7(3):153–159. Doi: 10.1177/2040622315627805.
    5. Gaspersz R, Nawijn L, Lamers F, Penninx B (2018). Patients with anxiety depression: an overview of prevalence, pathophysiology, and impact on course and outcome. Curr Opin Psychiatry, 31(1):17–25.
    6. https://adaa.org/understanding-anxiety/generalized-anxiety-disorder-gad
    7. GlobalData, Center for Pharma Intelligence, Epidemiology and Market Size Database. Based on peer-reviewed literature, disease registries, and primary research.
    8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024727/
    9. Kessler, RC, Petukhova, M., Sampson, NA, Zaslavsky, AM, & Wittchen, HU (2012). Twelve-month and lifetime prevalence and lifetime morbidity risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiatric Research, 21(3), 169-184.
    10. https://www.globenewswire.com/en/news-release/2022/10/27/2542715/0/en/Generalized-Anxiety-Disorder-Therapeutics-Market-Report-2022-to-2030-Abbvie-Inc- Pfizer-Inc-Eli-Lilly-and-Company-GSK-PLC-Abbott-Laboratories-Inc-and-Johnson-Johnson.html

    Cautionary Statements and Forward-Looking Statements

    Certain statements in this press release constitute forward-looking information. with respect to the historical facts contained in this press release, including without limitation statements regarding Cybin’s futures, strategies, plans, objectives, goals and targets, and statements that follow or contain the word “believe”; All statements other than statements, “expects”, “aims”, “intends”, “plans”, “continues”, “will”, “may”, “would”, “anticipates” , “estimate”, “estimate”, “forecast”, project”, “seek”, “should” or similar expressions or the negative thereof are forward-looking statements. Forward-looking statements in this news release include statements regarding the expected results and potential of the Company’s CYB004 program, the CYB004-E Phase 1 DMT clinical trial, and expected results. A planned timeline to provide updates on the CYB004 program and our plans to design proprietary drug development platforms, innovative drug delivery systems, new formulation approaches and treatment regimens for mental health conditions.

    These forward-looking statements are based on our management’s reasonable assumptions and estimates at the time such statements are made. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual future results to differ materially. These factors may cause the company’s actual results, performance or achievements to differ materially from its stated future results, performance or achievements. It is implied by such forward-looking statements. Such factors include, among others: fluctuations in general macroeconomic conditions; fluctuations in the securities market; expectations regarding the size of the psychedelic market. A company’s ability to successfully achieve its business objectives. plans for growth; political, social and environmental uncertainties; relationships with employees; the existence of laws and regulations that may impose restrictions on the markets in which we operate; Discussions and analysis of the Company’s management for the three and six months ended September 30, 2022 and the risks described in the Company’s Annual Information Form for the year ended March 31, 2022 cause. Contact the US Securities and Exchange Commission (www.sec.gov) regarding sedar.com and EDGAR. Forward-looking statements contained in this news release are based on what our management believes, or believed at the time, to be reasonable assumptions, but actual results may differ from such forward-looking statements. We cannot assure our stockholders that our forward-looking statements will be consistent with them. There may be other factors that cause results that are not expected, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. We undertake no obligation to update any forward-looking statements regarding beliefs, opinions, projections or other factors if they change, except as required by law.

    Cybin makes no claims of medical, therapeutic, or health benefits for products Cybin suggests. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory agencies have not evaluated claims regarding psilocybin, psychedelic tryptamines, tryptamine derivatives, or other psychedelic compounds or dietary supplements. The efficacy of such products has not been confirmed by accepted research. , or preventable. Vigorous scientific research and clinical trials are required. Cybin has not conducted any clinical trials regarding the use of the proposed product. References to the quality, consistency, efficacy and safety of a potential product do not imply that Cybin has so validated in clinical trials or that Cybin has completed such trials. Cybin’s failure to obtain the necessary approvals or research to commercialize its business could have a material adverse effect on Cybin’s financial results and operations.

    Neither Neo Exchange Inc. nor the NYSE American LLC Stock Exchange endorses or denies the contents of this news release and is not responsible for the adequacy or accuracy of any content contained herein.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleEffects of sleep habits on body weight
    Next Article High Emotions As Akara’s Wife, Kids Remember Ex-Governor One Year After His Death
    brainwealthy_vws1ex
    • Website

    Related Posts

    FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

    February 2, 2023

    How anxiety came to dominate the big business of medical marijuana cards in Pa.

    February 2, 2023

    How to Reduce Anxiety in Stressful Situations

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.